(TheNewswire)
Collaboration tobuild on positive Cell Pouch T1D Clinical Outcomes and preclinicalsuccess in Global Pharmaceutical Collaborations to developregenerative medicine therapeutic cures without life-longimmunosuppression medications across multiple diseases
An informationsession featuring Dr. Alice Tomei, a leading internationalexpert in immunoprotection and diabetes immunoengineering at the University ofMiami, will take place on September 20th, 2021, at 1:00 PM EDT
LONDON, ONTARIO - TheNewswire - September 16, 2021 - Sernova Corp. (TSXV:SVA)(OTC:SEOVF) (FSE/XETRA:PSH), a clinical-stage regenerative medicinecompany developing a ‘functional cure’ for type 1 diabetes (T1D)and other chronic diseases, announced today it has entered into aresearch agreement with the University of Miami to advance thedevelopment of our Cell Pouch™ cell therapy platform combined withthe novel conformal coating cellular immune protection technology.
Dr. Alice Tomei, of the renowned Diabetes ResearchInstitute (DRI) at the University of Miami Miller School of Medicine,is an associate professor and international expert in immunoprotectionand diabetes immunoengineering. As part of this importantcollaboration, Dr. Tomei and her team is working closely withSernova’s R&D team. The expert teams have developed a series ofkey preclinical and polymer characterization studies. In addition,work is being conducted to scale-up the conformal coating technologyprocess. The ultimate goal of this work is to support and acceleratethe anticipated clinical evaluation of the Cell Pouch platform withoutthe need for immunosuppression in patients with brittle T1D.
While the studies will focus on immune protection ofinsulin producing cells in the Cell Pouch, these technology advancesare expected to be directly relevant and applicable to an array ofcell technologies for treatment of multiple cell therapyapplications.
Dr. Tomei stated, “We have developed and optimizedthe conformal coating technologies over approximately twelve yearswith the goal of ensuring local immune protection of therapeutic cellswithout the need for life-long immunosuppression medications. Our hopeis that Sernova’s Cell Pouch technologies, which have already showninitial clinical benefit in patients with brittle T1D, when combinedwith conformally coated local immune protected islets, have thepotential to provide a significant advancement in the treatment ofpeople suffering from T1D.”
Dr. Toleikis, President & CEO of Sernova stated,“In our development of a therapeutic cell therapy approach for allpeople with T1D, we have used a systematic and stepwise strategy,first by combining our Cell Pouch in the clinic for patients withbrittle T1D with human donor islets protected with immunosuppression.Given the proven safety and efficacy of our Cell Pouch technologies,we are now thrilled to take this next step in our strategic approachby collaborating with Dr. Tomei’s team to advance the conformalcoating as a cellular local immune protection strategy for islettechnologies.”
“An information session will take place on September 20th, 2021, at1:00 PM EDT. The information session will feature Dr. Alice Tomei,associate professor at the University of Miami. During thisinformation session, Dr. Tomei will discuss the conformal coatingtechnology approach for local cellular immune protection and Sernovawill also provide a management update during this session," saidDr. Philip Toleikis, "Session attendees will be able to askquestions during a following Q&A period with Dr. Tomei and Sernovamanagement.”
The presentation will be made available onSernova's website before the call. Questions can be submitted to info@sernova.com prior to the call.
To register and access the Zoom link for this event, please click:
https://us02web.zoom.us/webinar/register/WN_iDuWzqW4R3COgQ_toI376A
Following the event, a recording will be available at www.sernova.com .
ABOUT SERNOVA
Sernova Corp is developing regenerative medicine therapeutic solutionsusing a medical device (Cell Pouch™) and immune protectedtherapeutic cells/tissues (i.e., human donor cells, corrected humancells and stem cell-derived cells) to improve the treatment andquality of life of people with chronic metabolic diseases such asinsulin-dependent diabetes, blood disorders including hemophilia, andother diseases treated through cellular production of proteins orhormones missing or in short supply within the body. For moreinformation, please visit www.sernova.com .
ABOUT SERNOVA’S CELL POUCHSYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel,proprietary, scalable, implantable macro- encapsulation devicesolution designed for the long-term survival and function oftherapeutic cells. The device upon implantation is designed toincorporate with tissue, forming highly vascularized tissue chambersfor the transplantation and function of therapeutic cells, which thenrelease proteins and hormones as required to treat disease. The CellPouch, along with therapeutic cells, has been shown to providelong-term safety and efficacy in small and large animal models ofdiabetes and has been proven to provide a biologically compatibleenvironment for insulin-producing cells in humans in a Canadianfirst-in-human study. Sernova is currently conducting a Phase I/IIstudy at the University of Chicago. Positive initial results have beenpresented at several international scientific conferences.
FOR FURTHER INFORMATION, PLEASECONTACT:
Investor Relations Sernova Corp.
Tel: (519) 858-5126
investor.relations@sernova.com
FORWARD-LOOKING INFORMATION
This release contains statements that, to the extent they are notrecitations of historical facts, may constitute “forward-lookingstatements” that involve various risks, uncertainties, andassumptions, including, without limitation, statements regarding theprospects, plans, and objectives of the company. Wherever possible,but not always, words such as "expects", "plans","anticipates", "believes", "intends","estimates", "projects", "potential for"and similar expressions, or that events or conditions"will", "would", "may","could" or "should" occur are used to identifyforward-looking statements. These statements reflect management’sbeliefs with respect to future events and are based on informationcurrently available to management on the date such statements weremade. Many factors could cause Sernova’s actual results,performances or achievements to not be as anticipated, estimated orintended or to differ materially from those expressed or implied bythe forward-looking statements contained in this news release. Suchfactors could include, but are not limited to, the company’s abilityto secure additional financing and licensing arrangements onreasonable terms, or at all; ability to conduct all requiredpreclinical and clinical studies for the company’s Cell Pouch Systemand/or related technologies, including the timing and results of thosetrials; ability to obtain all necessary regulatory approvals, or on atimely basis; ability to in-license additional complementarytechnologies; ability to execute its business strategy andsuccessfully compete in the market; and the inherent risks associatedwith the development of biotechnology combination products generally.Many of the factors are beyond our control, including those caused by,related to, or impacted by the novel coronavirus pandemic. Investorsshould consult the company’s quarterly and annual filings availableon www.sedar.com for additional information on risks and uncertaintiesrelating to the forward-looking statements. Sernova expresslydisclaims any intention or obligation to update or revise anyforward-looking statements, whether as a result of new information,future events or otherwise.
Copyright (c) 2021 TheNewswire - All rights reserved.